AbbVie's ABBV-1088 trial halted before results

NCT ID NCT06579300

Terminated Knowledge-focused Sponsor: AbbVie Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This was a Phase 1 study to check the safety and how the body processes ABBV-1088 in healthy adults, including Western, Han-Chinese, and Japanese participants. It also looked at how ABBV-1088 interacts with another drug, itraconazole. The study was terminated early, so no results are available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ABBV-1088
What could go wrong: This trial was terminated early, so no data on safety or effectiveness were collected. It is a very early Phase 1 study in healthy volunteers, not patients, so it cannot show any treatment benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY VOLUNTEER

Contacts and locations

Locations

Acpru /Id# 270552

Grayslake, Illinois, 60030, United States
CenExel ACT- Anaheim Clinical Trials /ID# 276423

Anaheim, California, 92801, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.